COST-EFFECTIVENESS OF EMPAGLIFLOZIN (JARDIANCE) IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN THE UK BASED ON EMPA-REG OUTCOME DATA

被引：10
|
作者：
Daacke, I [1 ]
Kandaswamy, P. [2 ]
Tebboth, A. [3 ]
Kansal, A. [4 ]
Reifsnider, O. [4 ]
机构：
[1] Boehringer Ingelheim GmbH & Co KG, Bracknell, Berks, England
[2] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[3] Boehringer Ingelheim UK, Bracknell, Berks, England
[4] Evidera, Bethesda, MD USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.1876
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB46
引用
收藏
页码：A673 / A673
页数：1
相关论文
共 50 条
  • [31] Empagliflozin in Patients With Type 2 Diabetes Mellitus (T2DM) and Renal Impairment (RI)
    Barnett, Anthony H.
    Mithal, Ambrish
    Manassie, Jenny
    Jones, Russell
    Rattunde, Henning
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2013, 62 : A286 - A286
  • [32] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) 10MG AND EMPAGLIFLOZIN (EMPA) 25MG IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) AS MONOTHERAPY IN THE UNITED KINGDOM
    Schroeder, M.
    Johansen, P.
    Willis, M.
    Neslusan, C.
    VALUE IN HEALTH, 2015, 18 (07) : A607 - A607
  • [33] THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN (FORXIGA®) VERSUS INSULIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN ENGLAND AND WALES
    Charokopou, M.
    McEwan, P.
    Lister, S.
    Callan, L.
    Bergenheim, K.
    Tolley, K.
    Roudaut, M.
    VALUE IN HEALTH, 2013, 16 (07) : A441 - A441
  • [34] IMPACT OF PATIENT WEIGHT TRAJECTORY ON COST-EFFECTIVENESS OF TREATMENTS OF TYPE 2 DIABETES MELLITUS (T2DM)
    Schroeder, M.
    Willis, M.
    Johansen, P.
    Girod, I
    Neslusan, C.
    Thompson, G.
    VALUE IN HEALTH, 2013, 16 (07) : A440 - A440
  • [35] Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
    Fitchett, David
    Zinman, Bernard
    Wanner, Christoph
    Lachin, John M.
    Hantel, Stefan
    Salsali, Afshin
    Johansen, Odd Erik
    Woerle, Hans J.
    Broedl, Uli C.
    Inzucchi, Silvio E.
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    Mortelmans, J.
    EUROPEAN HEART JOURNAL, 2016, 37 (19) : 1526 - 1534
  • [36] Effect of empagliflozin (EMPA) on diabetic ketoacidosis (DKA) in patients with type 2 diabetes (T2DM): pooled clinical trial data
    Lund, S.
    Solimando, F.
    Kohler, S.
    Zeller, C.
    Kaspers, S.
    DIABETOLOGIA, 2016, 59 : S26 - S27
  • [37] Empagliflozin facilitates sustained insulin dose reductions in patients with type 2 diabetes and cardiovascular disease: the EMPA-REG OUTCOME trial
    Vaduganathan, M.
    Sattar, N.
    Fitchett, D.
    Ofstad, A.
    Brueckmann, M.
    George, J. T.
    Verma, S.
    Mattheus, M.
    Wanner, C.
    Inzucchi, S. E.
    Zinman, B.
    Butler, J.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S275 - S275
  • [38] Cost-effectiveness of strict "get to goal" treatment directives in the treatment of younger patients with newly diagnosed type 2 diabetes mellitus (T2DM)
    Willis, M.
    Borg, S.
    Persson, U.
    Neslusan, C.
    VALUE IN HEALTH, 2007, 10 (06) : A260 - A260
  • [39] Cost-Effectiveness Analysis of Type 2 Diabetes Mellitus (T2DM) Treatment in Patients with Complications of Kidney and Peripheral Vascular Diseases in Indonesia
    Priyadi, Akhmad
    Permana, Hikmat
    Muhtadi, Ahmad
    Sumiwi, Sri A.
    Sinuraya, Rano K.
    Suwantika, Auliya A.
    HEALTHCARE, 2021, 9 (02)
  • [40] Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME®
    Kaku, Kohei
    Lee, Jisoo
    Mattheus, Michaela
    Kaspers, Stefan
    George, Jyothis
    Woerle, Hans-Juergen
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    Mortelmans, J.
    Strivay, M.
    Vereecken, G.
    Keymeulen, B.
    Lamkanfi, F.
    CIRCULATION JOURNAL, 2017, 81 (02) : 227 - +
12345